Loading
In 476 women with early triple-negative cancer who had no chemotherapy, more lymphocytes in the tumour still meant fewer relapses, and stage I patients with 30% or more had a 97% chance of no distant relapse at five years.
Individual data from 476 TNBC patients not treated with chemotherapy at four centres (1989 to 2015; median age 64, median tumour 1.6 cm, 83% node-negative) were pooled. Median sTILs were 10% (interquartile range 4 to 30%). In multivariable analysis each 10% increment gave hazard ratios of 0.90 (iDFS), 0.86 (D-DFS) and 0.88 (OS). Stage I patients with sTILs 30% or more (74) had five-year iDFS 91%, D-DFS 97% and OS 98%.
TILs are prognostic without chemotherapy, which is what a de-escalation biomarker has to show before trials omit treatment on its basis.
Shares Sherene Loi, Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Sherene Loi, Giuseppe Curigliano, Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer.
Shares Giuseppe Curigliano, Annals of Oncology, Triple-negative breast cancer (TNBC).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Giuseppe Curigliano, Annals of Oncology, Triple-negative breast cancer (TNBC).
Shares Giuseppe Curigliano, Annals of Oncology, Triple-negative breast cancer (TNBC).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Tumour-infiltrating lymphocytes (TILs), Early triple-negative breast cancer, Triple-negative breast cancer (TNBC).